Bone/Mineral Metabolism News

Teva Pharmaceuticals announced FDA approval of a generic version of Forteo in the U.S. for certain women and men with osteoporosis, according to a company press release.

Transgender people who use gender-confirming hormone therapy long term have increases in bone mineral density back to levels observed before pubertal suppression, according to findings published in JAMA Pediatrics.

Current menopause smartphone apps require more information on osteoporosis, expert input and better quality, functionality and simplicity of use and understanding for the general public, researchers reported.

Postmenopausal women who stopped or never used hormone therapy over a 5-year period experienced a loss in bone density, whereas bone density was maintained for those who continued treatment, researchers reported in Menopause.

Adults with Graves’ disease do not have an increased risk for an osteoporosis-related fracture later in life compared with those without Graves’ disease, according to data from a retrospective study published in Thyroid.

The FDA has expanded its accelerated approval of an injectable therapy for treating achondroplasia to include children of all ages, according to a press release.

Muscle mass as measured through high-resolution peripheral quantitative CT may not interact with bone measures to affect the risk for fractures among older men, though more studies are needed, according to study data.

The FDA approved palovarotene capsules as the first treatment for people with the rare bone disease fibrodysplasia ossificans progressiva, according to an industry press release.

SANTA FE, N.M. — In this video exclusive, Michael R. McClung, MD, discusses strategies for drug holidays and transitions between osteoporosis therapies.

SANTA FE, NEW MEXICO — In this video exclusive, Christopher Kovacs, MD, FRCP, FACP, FACE, talks about osteoporosis and fragility fractures associated with pregnancy and lactation.